SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

$SLV is trending as silver nears multi-decade highs, sparking community discussion around a potential short squeeze and anticipation of further gains. Some community members are discussing theories around market manipulation and speculating about triple-digit prices, while others highlight the potential for a significant breakout after years of price suppression. Investors are closely watching silver's momentum amid concerns about inflation and the dollar's stability.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as the community rallies behind the stock, citing potential short squeezes and government support amid increasing demand for critical minerals. The stock's price movement and sector momentum are fueling discussions, with many anticipating a continued climb. Bullish investors express strong conviction in TMC's long-term prospects.

Aventus Network

Aventus Network ($AVT) is trending, with community members discussing its potential and recent partnerships. Some are pointing to its low market cap and real-world applications in cargo management as reasons for optimism. Mentions of its integration with Polkadot and listing on Coinbase are also circulating.

Global Health Solutions Inc is an American company that works with partners to eliminate diseases that have plagued humanity for centuries and protect the health of populations by helping countries build strong health systems. The private company is located in the US. The company brings together key stakeholders around the world with a common goal to stop diseases and strengthen health systems through powerful partnerships. The company consists of programs and focus areas that cover a range of health issues including neglected tropical diseases, infectious diseases, vaccines, field epidemiology, public health informatics, health workforce development, and health ethics. The company's end goal is to eliminate diseases and protect the health of populations.

Turn Therapeutics Inc.

Turn Therapeutics Inc

Turn Therapeutics ($TTRX) is trending after its recent IPO, with the community discussing its potential for significant gains. Some traders are cautious, pointing to valuation concerns and possible formations on the minute chart, while others see it as the next stock poised for a substantial surge, drawing comparisons to other recent high-flying IPOs.

First Majestic Silver Corp. engages in the production, development, exploration and acquisition of mineral properties. It owns and operates producing mines in México including the La Encantada Silver Mine, La Parrilla Silver Mine, San Martin Silver Mine, La Guitarra Silver Mine, Del Toro Silver Mine, Santa Elena Silver & Gold Mine, and San Dimas Silver & Gold Mine. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver is trending as spot silver prices reach new highs, sparking excitement among investors. The community is actively discussing loading up on silver miners and anticipating further gains, drawing comparisons to gold's previous rallies. Some are pointing out the potential for silver miners to go mainstream, while others are debating realistic price targets.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

SERV is trending after announcing a strategic partnership with DoorDash, expanding its autonomous delivery robot service nationwide and outside of the Uber Eats ecosystem. Community members are discussing the potential for increased delivery volume and expansion into new markets, with some eyeing price targets. The stock is gaining traction as investors show interest in the autonomous last-mile delivery space.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending as investors speculate about a potential acquisition following increased M&A activity in the metabolic disease space, highlighted by the recent AKRO and MTSR deals. Community discussions revolve around potential buyout offers and the possibility of a short squeeze, with many believing VKTX is undervalued given its pipeline and recent data. The focus is now shifting towards MASH opportunities, adding another layer of potential value for the company.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending amid discussions of a potential short squeeze, driven by high short interest and growing optimism around its transition to AI/HPC data centers; the community is closely watching key resistance levels and anticipating a breakout. Positive sentiment is further fueled by Google's backing and potential approval of the Cayuga site, which could unlock significant capacity and revenue opportunities. Some traders are comparing it to the early stages of other AI plays.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense & Security Solutions is trending as investors discuss its potential as a key player in the evolving defense sector, particularly regarding drone and hypersonic technology. Community members highlight the company's innovative solutions, potential for partnerships, and rising defense spending as catalysts, while also speculating on possible acquisition targets. Some investors believe KTOS is currently undervalued compared to other defense giants, while others express concern about an overvalued status.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta Air Lines is trending after reporting strong Q3 earnings, exceeding expectations and raising full-year guidance, boosting investor confidence and lifting the entire airline sector. The community is actively discussing whether to hold or sell, anticipating further gains and a potential rise to new highs. Corporate sales and premium revenue growth reflect strong demand, and the CEO expresses optimism for continued momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock?

PROKIDNEY CP (PROK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Best Momentum Stocks to Buy for July 17th

PROK, ROKU and PHAR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 17, 2025.

New Strong Buy Stocks for July 17th

PHAR, ROKU, PROK, MAG and KRP have been added to the Zacks Rank #1 (Strong Buy) List on July 17, 2025.

ProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy?

Does ProKidney Corp. (PROK) have what it takes to be a top stock pick for momentum investors? Let's find out.

PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study

Shares of ProKidney jump 515% after its kidney cell therapy shows strong efficacy in a Phase II diabetes-related CKD study.

Shares of ProKidney surged more than 500% on Tuesday following upbeat results from its Phase 2 REGEN-007 study and a price target upgrade from Citi.&nbsp;The company is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease (CKD) and diabetes.Citi raised its price target to $9 from $6 and maintained a ‘Buy’ rating, saying the early data “exceeded expectations.”&nbsp;The firm increased the probability of success for the program to 60%, citing statistically significant efficacy seen in Group 1 of the trial, which may support accelerated approval in Phase 3 subject to FDA feedback.The REGEN-007 study showed that kidney function decline was reduced by 78% in group 1 after rilparencel treatment.&nbsp;Patients who received two injections approximately three months apart experienced an improvement in their annual eGFR slope from -5.8 to -1.3 mL/min/1.73 m², representing a statistically and clinically meaningful difference.However, Bank of America was more cautious, reiterating its ‘Underperform’ rating and $1 price target.&nbsp;The firm flagged the absence of a sham comparator, lack of a conference call to discuss the data, and regulatory ambiguity. It stated that the stock’s sharp rally “looks overdone,” especially given that detailed data are likely to be withheld for a future medical meeting.ProKidney reported that no serious side effects were observed in the trial, and the safety results were consistent with earlier studies.&nbsp;Rilparencel already holds RMAT status from the FDA and is also being tested in a larger Phase 3 trial called PROACT 1.&nbsp;The company noted that early signals from REGEN-007 reinforce previously observed efficacy trends in high-risk patient subgroups.On Stocktwits, retail sentiment for <a href="https://stocktwits.com/symbol/PROK">ProKidney</a> was ‘extremely bullish’ amid ‘extremely high’ message volume.One user anticipated strong momentum ahead, saying they were “thinking 100% gain tomorrow.”<stembedurl>https://stocktwits.com/MarketMana/message/620282357</stembedurl>Another poster struck a more cautious but optimistic tone, noting that while they’d “love for this ticker and its well-deserving product [to have] a double-digit run,” biotech stocks often see profit-taking after big moves.&nbsp;They said short sellers could enter soon but saw long-term potential, saying, “If Phase III pans out and it gets FDA approval, it could make you a millionaire.”<stembedurl>https://stocktwits.com/nomendivitiae/message/620278285</stembedurl>ProKidney’s stock has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

ProKidney (PROK) is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease/ Photo credit: Getty Images

ProKidney Stock Skyrockets On Positive Trial Data; Citi Sees 60% Chance Of Success

The treatment, rilparencel, showed a 78% improvement in kidney function decline in one dosing group, with no serious safety issues reported, supporting its ongoing evaluation in a larger Phase 3 trial.

Equity

Kuehn Law Encourages Investors of ProKidney Corp. to Contact Law Firm

Kuehn Law Encourages Investors of ProKidney Corp. to Contact Law Firm Kuehn Law Encourages Investors of ProKidney Corp. to Contact Law Firm PR Newswire NEW YORK, Jan. 31, 2025 NEW YORK, Jan. 31, 2025...

Futures Drop Ahead Of CPI, FOMC; Euro Slumps After Weekend Election Shock

Futures Drop Ahead Of CPI, FOMC; Euro Slumps After Weekend Election Shock

 US equities were poised for modest losses to start the week after underlying indexes hit a new all time high on...

ProKidney appoints Ulrich Ernst as EVP, technical operations

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations

Dr. Ulrich Ernst joins as Executive Vice President of Technical Operations with a deep background and expertise in process development and manufacturing of cell therapies Mr. Lucio Tozzi joined in...

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.

ProKidney Corp - Ordinary Shares - Class A

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$3.28
Prev Close	$3.26
Open	$3.28
Dividend Yield	0.00%
50-Day Moving Average	$2.56
Beta	2.15
Avg. Volume	2.26M
PE Ratio	-5.78

52-Week High	$7.13
52-Week Low	$0.4603
Market Capitalization	$440.08M
EPS (Annual)	-$0.6249
Price to Book	-0.43
Revenue Per Employee	$372.55
Enterprise Value/EBITDA	N/A

PROK
ProKidney Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PROK News

PROK ProKidney Corp